App-Quantinova.ai

HBcrAg, HBV‐RNA declines in A Phase 2a Study Evaluating the Multi‐dose Activity of ARB‐1467 in HBeAg‐Positive and Negative Virally Suppressed Subjects with Hepatitis B

Kosh Agarwal - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

N/A

Genome‐wide association study (GWAS) to identify genetic risk factors that increase susceptibility to anti‐tuberculosis drug‐induced liver injury (ATDILI).

Paola Nicoletti - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

Multiple HLA B*57 alleles, sharing the amino acid residue Valine97, are associated with drug‐induced liver injury due to flucloxacillin in a European population.

Paola Nicoletti - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Drug-induced liver injury

Flopen

Sensitive detection of human drug‐induced liver injury by measurement of microRNA‐122 using single molecule arrays

James W. Dear - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Drug-induced liver injury

Acetaminophen

C‐BREEZE 2: Efficacy and Safety of a Two‐Drug Direct‐Acting Antiviral Agent (DAA) Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Genotype (GT)1,2, 3, 4, or 6

Eric Lawitz - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hepatitis C

Uprifosbuvir

Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment‐Naive Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis

Steven L. Flamm - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Cirrhosis

Glecaprevir and Pibrentasvir

Significant and Sustained Improvement of Health‐Related Quality of Life (HRQL) Scores in Patients with Hepatitis C (HCV) and Sustained Virologic Response (SVR)

Zobair M. Younossi - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

Sofosbuvir

Time Trends in Major Hepatic Complications in Primary Biliary Cholangitis: incidence and transplant‐free survival

Maren H. Harms - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Primary biliary cirrhosis

N/A

Bilirubin is Predictive of Transplant‐free Survival Even Within the Normal Range in Primary Biliary Cholangitis Patients

Carla F. Murillo Perez - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Primary biliary cirrhosis

Alkaline phosphatase

Effects of B‐Cell depleting therapy (Rituximab) on liver biochemistry in UDCA‐responsive patients: results from a randomised controlled trial of Rituximab in fatigued PBC patients (RitPBC).

Amardeep Khanna - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Rituximab

Exercise dramatically improves age‐related, inflammation‐driven liver damage and cancer.

Arianna Bianchi - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

New insights from the SILVER study; a 50 % reduction in Calcineurin Inhibitors at day 30 does not impact on long‐term renal function after liver transplantation

Bettina M. Buchholz - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Rapacan

Gut Microbial Functional Changes After Liver Transplant Can Modulate Infection Risk And Increase Atherogenic Metabolites

Jasmohan S. Bajaj - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Advanced machine learning techniques to identify a panel of biomarkers that identify nonalcoholic steatohepatitis

Saisakul Chernbumroong - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic steatohepatitis

N/A

Development and Validation of the Collagen Neo‐Epitope Biomarker Pro‐C3 “FIB‐C3 Score” for Detection and Staging of Advanced NonAlcoholic Fatty Liver Disease in a Large International Multi‐Centre Patient Cohort

Marie P. Boyle - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic fatty liver disease

N/A

Phase 2 open‐label efficacy and safety study of the apical sodium‐dependent bile acid transporter inhibitor maralixibat in children with progressive familial intrahepatic cholestasis: 48‐week interim efficacy analysis

Richard J. Thompson - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Familial cholestasis

Lopixibat chloride

Improvement in GGT predicts event‐free survival in primary sclerosing cholangitis regardless of ursodeoxycholic acid treatment: data from the Pediatric PSC Consortium

Mark R. Deneau - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Primary sclerosing cholangitis

Ursodeoxycholic acid

Transferrin Is Downregulated in Alcoholic Hepatitis and Predicts Short‐term Survival

Karim Hamesch - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Alcoholic hepatitis

N/A

Association between disease‐predisposing HLA DR3/DR7/DR13 genes with numeric impairment of immunoregulatory T‐cells in patients with autoimmune hepatitis/sclerosing cholangitis

Pengyun Wang - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Primary sclerosing cholangitis

N/A

Transcriptome profiles of NK and T cells regulating immune control in chronic hepatitis B, proximate to patients treated with Pegylated Interferon alpha‐Nucleos(t)ide analogue (NA) sequential therapy compared to de novo NA therapy.

Upkar S. Gill - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

Pegylated interferon alpha

Filters

45280 Abstracts